Acumen Pharmaceuticals will hold a conference call today to discuss the positive topline results from the Phase 1 INTERCEPT-AD trial of ACU193, the first clinical-stage AbetaO targeting antibody therapy in early AD. Acumen will host a webcast presentation and conference call for analysts and investors today, July 17, 2023, at 8:00 a.m. ET to discuss the topline data from the INTERCEPT-AD clinical trial. The webcast will feature members of Acumen’s leadership team as well as Steven DeKosky, M.D., Deputy Director of the McKnight Brain Institute at the University of Florida and member of Acumen’s scientific advisory board, and Lawrence Honig, M.D., Ph.D., Director of the New York State Center of Excellence for Alzheimer’s Disease at Columbia University and an INTERCEPT-AD trial investigator.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ABOS:
- Acumen Pharmaceuticals Announces Proposed Public Offering of Common Stock
- Acumen Pharma (NASDAQ:ABOS) Skyrockets on Promising Phase 1 Data in Alzheimer’s Disease
- Acumen Pharmaceuticals to Hold Conference Call to Discuss Positive Topline Results from First-in-Human Phase 1 Study of ACU193 for Early Alzheimer’s Disease
- Acumen holds a conference call
- Acumen presents topline results from first-in-human Phase 1 study of ACU193